In structured interviews, patients with T1D highlighted their perception of real-world benefits from GLP1-RA and SGLT2 inhibitors, though the associated risk exceeded that observed in RCTs [121]. This evidence concerns the gene SLC5A2 and type 1 diabetes mellitus.